David Cullinane
Question:2001. Deputy David Cullinane asked the Minister for Health further to Parliamentary Question No. 612 of 5 July 2022, the reason that the HSE does not have a mechanism to detail the costs associated with the extension in use of certain drugs to new indications, new uses by way of comparison of diagnostic information data with its reimbursement systems. [41618/22]
View answer